An open label study comparing the safety and efficacy, and the pharmacokinetic characteristics of once a day dosing vs twice a day dosing of Neoral in de novo recipients of a renal allograft. The study will also look at the efficacy of Neoral when used as a maintenance immunosuppresive agent. Patients will be followed for 6 months to compare the different effects of the two dosing regimens; they will have three PK profiles to compare these characteristics in the different dosing profiles, and safety will be monitored by frequent blood chemistries and GFR's.
Showing the most recent 10 out of 336 publications